Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Harvard Bioscience Inc

NASDAQ: HBIO · Industrial Applications and Services · 3 alerts · CIK 1123494

Share price
$8.91Close, Nov 16
Market cap
$40.7M
Shares outstanding
4.57MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Harvard Bioscience Inc filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Harvard Bioscience Q3 2026 Results: Net Loss of $2.62M, Loss Widens

Harvard Bioscience reported revenues of $22.2 million for Q3 2026, a slight increase from $20.6 million in the prior year, though the company recorded a net loss of $2.6 million. For the nine months ended September 30, 2026, the net loss was $9.0 million compared to a $53.9 million loss in 2025, which had been driven by a significant $48.0 million goodwill impairment charge.

Key figure
Net loss $2.62M
7:00 AM ET 8-K
Financial Results

Harvard Bioscience Financial Results

Harvard Bioscience reported Q3 2026 revenue of $22.2 million, an 8% increase year-over-year, driven by strong demand from CROs and customers in China. The company reported a net loss of $2.6 million for the quarter and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%.

Term
Q3 2026

“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products.”

John Duke, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.